The rising interest in GLP-1 agonists for diabetes has sparked a question about formats: skin-applied devices versus pills . Typically, GLP-1 therapies were exclusively available in oral form, but the introduction of skin applications offers a new option . Skin applications might suit individuals facing issues with pills , those seeking to reduc… Read More